Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/Chemo as a SOC for Resectable NSCLC

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

Related Keywords

Canada ,Quebec ,Bristol Myers Squibb Medarex ,Neoadjuvant Opdivo ,Kaplan Meier ,Xenetic Biosciences ,Jonathand Spicer ,Astrazeneca ,Bristol Myers Squibb ,Mcgill University Health Centre ,Pfizer ,Novartis ,Amgen ,Protalix Biotherapeutics ,New England Journal ,Bristol Myers ,